Yen Thi Hong Cu

Learn More
Despite more than two decades of research and development on nucleic acid vaccines, there is still no commercial product for human use. Taking advantage of the recent innovations in systemic delivery of short interfering RNA (siRNA) using lipid nanoparticles (LNPs), we developed a self-amplifying RNA vaccine. Here we show that nonviral delivery of a 9-kb(More)
Self-amplifying messenger RNA (mRNA) of positive-strand RNA viruses are effective vectors for in situ expression of vaccine antigens and have potential as a new vaccine technology platform well suited for global health applications. The SAM vaccine platform is based on a synthetic, self-amplifying mRNA delivered by a nonviral delivery system. The safety and(More)
Rapid, multiplexed, sensitive and specific molecular detection is of great demand in gene profiling, drug screening, clinical diagnostics and environmental analysis. One of the major challenges in multiplexed analysis is to identify each specific reaction with a distinct label or 'code'. Two encoding strategies are currently used: positional encoding, in(More)
DNA can be used as a generic delivery vector in addition to its genetic role as a antigen expression vector. This is inspired in part by the fact that DNA molecules are true polymers. Surprisingly, DNA molecules have not been used as a delivery vector material. This is probably due to the fact that almost all DNA have only two shapes: linear or circular.(More)
Nucleic acid-based vaccines such as viral vectors, plasmid DNA (pDNA), and mRNA are being developed as a means to address limitations of both live-attenuated and subunit vaccines. DNA vaccines have been shown to be potent in a wide variety of animal species and several products are now licensed for commercial veterinary but not human use. Electroporation(More)
Background Self-amplifying RNAs (replicons) of positive-strand viruses are useful vectors for delivering vaccine antigens. Novartis has developed a self-amplifying mRNA (SAMTM) vaccine platform to take advantage of cell-free RNA production and synthetic non-viral delivery systems. In this study, the safety, immunogenicity, and efficacy of HIV-SAMTM vaccines(More)
Methods Novartis VRPs are being further tested using a current state-of-the art physiologically relevant low-dose SIV virus swarm challenge. To meet the need for the large numbers of VRP an alphavirus packaging cell line (PCL) was used for VRP production. We manufactured, characterized, stability and small animal potency tested VRPs expressing SIVmac239(More)
Background Self-amplifying RNAs (replicons) of positive-strand viruses such as alphaviruses are potentially safe and useful vectors for delivering vaccine antigens. We previously showed that recombinant alphavirus replicon particles (VRP), used in prime-boost regimen with Env in MF59 protein protected rhesus macaques against mucosal challenge with(More)
Results We evaluated systemic and mucosal immune responses in mice and rabbits using the SAMTM platform expressing HIV-1 gp140 (HIV-SAMTM vaccine) prime, protein/MF59 vaccine boost regimen for both HIV-1 Clade B and C Env antigens. In mice, the primed Env-specific IgG response to 1 μg of the HIV-SAMTM vaccine was comparable to a 10 μg dose of an identically(More)
  • 1